LY-310762

From WikiMD's Wellness Encyclopedia

LY-310762 is a drug that was developed for the treatment of migraines. It acts as a 5-HT1D receptor antagonist, and has a novel mechanism of action. Despite showing promise in animal models, it was not effective in reducing migraine symptoms in a clinical trial.

History[edit | edit source]

LY-310762 was developed by Eli Lilly and Company, a pharmaceutical company based in the United States. The drug was designed to target the 5-HT1D receptor, a subtype of the 5-HT receptor that is thought to be involved in the pathophysiology of migraines.

Mechanism of action[edit | edit source]

LY-310762 is a 5-HT1D receptor antagonist. The 5-HT1D receptor is a G protein-coupled receptor that is activated by the neurotransmitter serotonin. By blocking this receptor, LY-310762 is thought to inhibit the release of calcitonin gene-related peptide, a molecule that is involved in the transmission of pain signals in the brain.

Clinical trials[edit | edit source]

Despite showing promise in animal models, LY-310762 was not effective in reducing migraine symptoms in a clinical trial. The reasons for this lack of efficacy are not fully understood, but it is thought that the drug may not have been able to reach the necessary concentrations in the brain due to poor bioavailability.

See also[edit | edit source]

LY-310762 Resources
Wikipedia
WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD